Healthcare DIVE January 31, 2018
More than a year after the landmark 21st Century Cures Act was signed prodding the government to evaluate use of real-world evidence, payers are weighing the role it can play to tamp down on high-cost treatments.
The bipartisan law mandated the Department of Health and Human Services create a program to evaluate the use of evidence gleaned outside randomized controlled clinical trials. The movement toward value-based care is spurring more life science companies to invest in the evidence.
Payers see their own opportunity, but some are still wary.
“When it comes to real-world evidence, especially for drug approval, there is a lot of skepticism about using less than the most rigorous randomized controlled trials,” Steve Miller, Express Scripts’ chief medical...
Today's Sponsors
Today's Sponsor